Skip to main content
OpenTrials
Completed

NCT Number: NCT00622440

Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream

The purpose of this study is to find out if a Chinese herbal cream is effective in treating HSIL (high-grade squamous intraepithelial lesions, also known as HGAIN, or high-grade anal intraepithelial neoplasia).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anus Neoplasms Anus Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases Rectal Neoplasms

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of California, San Francisco

San Francisco, California, 94143, United States

About this study

The purpose of this study is to test a new noninvasive topical cream, AIJP (Arnebia Indigo Jade Pearl), for treatment of precancerous anal lesions in order to prevent their progression to anal cancer. AIJP is a topical Chinese herbal cream that has been specifically designed to treat people with the cancer precursor lesions caused by human papillomavirus (HPV). In general, HPV infection is a key factor in development of cervical, anal and vulvar cancers. People with HIV are especially vulnerable to develop anal cancer associated with HPV. It is known that prior to development of anal cancer a person develops a precancerous condition known as a high-grade squamous intraepithelial lesion (HSIL). Treatment of the HSIL can prevent progression to anal cancer. Current therapies for HSIL and anal cancer are highly invasive. A new effective noninvasive topical therapy for precancerous HSIL could have a high impact on prevention of anal cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Anal HSIL confirmed by biopsy no more than 30 days prior to entry
  • Anal HSIL deemed not amenable to therapy or participant declines routine ablative therapy
  • HIV positive
  • Stable HIV treatment regimen for at least 8 weeks prior to entry
  • At least 18 years of age
  • Women of childbearing potential must use contraception
  • Platelet count above 70,000/mm3 within 30 days prior to entry
  • ANC greater or equal to 1000/mm3 within 30 days prior to entry
  • Creatinine less then or equal to 1.5 times ULN within 30 days prior to entry
  • AST and ALT less than or equal to 3 times ULN within 30 days prior to entry

Exclusion criteria

  • Prior history of invasive anal, cervical, vaginal, or vulvar cancer
  • Pregnancy or lactation and breast-feeding
  • Must not participate in a conception process including sperm donation
  • Medical or psychiatric illness that precludes ability to give informed consent or is likely to interfere with ability to comply with protocol
  • Known allergy to any topical cream components
  • Patients with lesions clinically suspicious per HRA examiner for early progression (less than one year) to anal cancer

Treatment and study plan

AIJP (Arnebia Indigo Jade Pearl)

Drug

Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.

Placebo

Drug

Placebo twice daily for 48 weeks.

Primary outcomes

  1. Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL)

    Time frame: Baseline, Week 48, and Week 60; up to 60 weeks

    Response assessed 12 weeks after treatment.

    Late Clinical Response (LCR): HSIL present at week 48 but none at week 60, with two independent reviews in agreement that HSIL absent at week 60.

    Complete response (CR): No HSIL on histology or cytology at weeks 48 or 60 (caveat: if HSIL at week 60, blinded chart notes and photographs were reviewed by two clinicians, and decision was reached by agreement or consensus whether HSIL had been missed at week 48. Cases that reviewers independently agreed had not been missed at week 48 were considered true recurrences)

    Partial Clinical Response (PCR): HSIL on cytology with no HSIL histology, or improvement >50% in the number of lesions with HSIL, or an improvement >50% in lesion size, area, or clinical characteristics (e.g. acetowhite staining, Lugol's staining, or vascular changes were improved)

    No Response (NR): HSIL present at weeks 48 & 60 on histology, or improvement ≤ 50% in number, size, area or characteristics.

Secondary outcomes

  1. Treatment Adherence

    Time frame: Up to 48 weeks

    Percent of recommended applications of cream reported in participant diary.

    >75% = Excellent >50%-75% = Good >25%-50% = Poor <25% = Non-adherent

  2. Response With >50% Adherence

    Time frame: Baseline, Week 48, and Week 60; up to 60 weeks

    Response assessed 12 weeks after treatment (week 60), by treatment adherence assessed at 48 weeks.

    Late Clinical Response (LCR): HSIL present at week 48 but none at week 60; two independent reviews agree HSIL absent at week 60.

    Complete response (CR): No HSIL on histology or cytology at weeks 48 or 60 (caveat: if HSIL at week 60, blinded chart notes and photographs reviewed by two clinicians, with decision by agreement or consensus whether HSIL had been missed at week 48. Cases that reviewers independently agreed had not been missed at week 48 were considered true recurrences)

    Partial Clinical Response (PCR): HSIL on cytology with no HSIL histology, or improvement >50% in number of lesions with HSIL, or improvement >50% in lesion size, area, or clinical characteristics (e.g. acetowhite staining, Lugol's staining, or vascular changes improved)

    No Response (NR): HSIL present on histology, or improvement ≤ 50% in number, size, area or characteristics.

  3. Response With >75% Adherence

    Time frame: Baseline, Week 48, and Week 60; up to 60 weeks

    Response assessed 12 weeks after treatment (week 60), by treatment adherence assessed at 48 weeks.

    Late Clinical Response (LCR): HSIL present at week 48 but none at week 60; two independent reviews agree that HSIL absent at week 60.

    Complete response (CR): No HSIL on histology or cytology (caveat: if HSIL at week 60, blinded chart notes and photographs were reviewed by two clinicians, and decision was reached by agreement or consensus whether HSIL had been missed at week 48. Cases that reviewers independently agreed had not been missed at week 48 were considered true recurrences)

    Partial Clinical Response (PCR): HSIL on cytology with no HSIL histology, or improvement >50% in the number of lesions with HSIL, or an improvement >50% in lesion size, area, or clinical characteristics (e.g. acetowhite staining, Lugol's staining, or vascular changes were improved)

    No Response (NR): HSIL present on histology, or improvement ≤ 50% in number, size, area or characteristics.

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Spring Wind Herbs

Registry information

Official study title

Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream

Acronym: AIJP

Important dates

Study start
2008
Primary completion
2012
Study completion
2012
First posted
Feb 25, 2008
Registry last updated
Apr 24, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.